836 Results
Sort By:
Published on November 16, 2018
Nebula Genomics, a personal genomics company whose co-founders include George Church, PhD, has launched a platform enabling users to have their whole genome sequenced in return for sharing access to their genomic data. Users seeking immediate sequencing of their personal genome can buy the service starting at $99—a reduction in…
Published on November 15, 2018
A Vanderbilt University Medical Center (VUMC) subsidiary, Nashville Biosciences, has agreed to make summary data from the VUMC-created BioVU clinico-genomic research database available through BC Platforms’ global biobank platform BCRQUEST.com, the companies said today. The value of the partnership was not disclosed. Nashville Biosciences was spun out of VUMC in…
Published on November 12, 2018
Newly published research shows that a saliva-based biomarker panel and associated algorithm could improve the ability to accurately identify children with autism spectrum disorder (ASD) in its earliest stages, according to Quadrant Biosciences. Researchers demonstrated that a panel of 32 small RNAs could differentiate children with autism from children exhibiting…
Published on November 2, 2018
Illumina says its planned approximately $1.2 billion acquisition of Pacific Biosciences, announced yesterday, will broaden clinicians’ access to the companies’ complementary technologies, especially PacBio’s long-read sequencing. The companies said their deal will create a sequencing powerhouse that will combine Illumina’s short-read technologies with PacBio’s long-read sequencing capabilities more suitable for…
Published on November 1, 2018
The Icahn School of Medicine at Mount Sinai has recruited computational biologist Adam Margolin, Ph.D., to lead its new $200 million precision medicine program, which it says will “radically” speed up drug development by integrating large-scale data analysis and advanced genomic technologies. Dr. Margolin—who was previously at Oregon Health &…
Published on November 1, 2018
At the Clinical Biomarkers and World CDx Conference, held recently in Boston, industry and academic scientists convened to address approaches to enhancing and validating the next generation of predictive biomarkers and promoting the adoption of high-value precision medicines and diagnostic testing worldwide. Basing Prognoses on Measures of Immune Cell Morphology…
Published on October 22, 2018
Next-generation sequencing (NGS) is justly credited with improvements such as cost reductions and throughput increases. NGS, however, will need other kinds of improvements if it is to expand its presence in clinical applications. Historically, NGS technology has been used to investigate specific mutations in select sets of genes or genetic…
Published on October 5, 2018
Personal Genome Diagnostics (PGDx) has won $42 million in financing from Innovatus Capital Partners that the company said will support its strategic initiative to bring regulated in vitro diagnostic (IVD) genome testing to cancer patients and their physicians worldwide. PGDx specializes in high-throughput, next-generation sequencing and proprietary algorithms to identify…
Published on September 24, 2018
Foundation Medicine announced that its liquid biopsy test for solid tumors, FoundationOne Liquid, is commercially available in the United States. The test, which uses only a few mL of blood analyzes 70 genes that drive cancer growth while also analyzing microsatellite instability (MSI) and important biomarker to help inform the selection…
Published on September 24, 2018
Epic Sciences said today its liquid biopsy blood test showed in a study that it can help physicians select prostate cancer patients who are likely to benefit from a Pfizer prostate-specific membrane antigen (PSMA)-targeted therapy candidate known as BIND-014 before the start of treatment. Researchers from Epic and Memorial Sloan…
Published on September 20, 2018
Predicine and Flagship Biosciences said today they will partner to provide complimentary and comprehensive biomarker profiling for immuno-oncology clinical trials, through a collaboration whose value was not disclosed. The collaboration will combine Predicine’s GeneRADAR molecular insights platform with Flagship’s artificial intelligence-enabled computational tissue analysis (cTA) digital pathology platform, with the…
Published on September 12, 2018
With more knowledge than ever before, the field of medicine is on a path toward more personalized care, where the right patient receives the right therapy, at the right time. To help physicians provide this next level of care to patients, clinical decision support (CDS) systems are evolving to incorporate…
Published on September 6, 2018
Guardant Health, the developer of genomic liquid biopsy tests focused on detecting cancer, will seek to raise up to $100 million in gross proceeds through an initial public offering (IPO), according to an S-1 registration statement filed yesterday with the U.S. Securities and Exchange Commission. Guardant didn’t spell out how…
Published on September 3, 2018
CRISPR-Cas9 has, for the first time, been tested by systemic delivery in a large animal—and the results are striking. Working in a dog model of Duchenne muscular dystrophy (DMD), the gene editing not only restored the expression of the protein dystrophin, it also improved muscle histology in the dogs. Eric…
Published on August 29, 2018
Biodesix said today that its VeriStrat proteomic blood test has shown its prognostic value for patients with non-small cell lung cancer (NSCLC) in a recently-published study. VeriStrat showed itself to be a significant predictor of outcomes, independent of clinical variables that included ECOG Performance Status categories, epidermal growth factor receptor…